Imunon to present Phase 3 OVATION 3 study of IMNN-001

IMUNON (IMNN) announced that it has been invited to present a trials-in-progress abstract on the ongoing Phase 3 OVATION 3 clinical trial of IMNN-001, its investigational therapy for the treatment of women with newly diagnosed advanced ovarian cancer, at the 2025 Annual Global Meeting of the International Gynecologic Cancer Society, IGCS, being held November 5-7, 2025 in Cape Town, South Africa. The study is supported with unprecedented OS data from a large, 112-patient, randomized Phase 2 study showing the following: Median 13-month increase in OS and median 3-month increase in PFS in IMNN-001 treatment arm compared to standard of care alone. Better therapeutic effect observed with IMNN-001 treatment compared to the control arm. Use of poly ADP-ribose polymerase inhibitors as part of maintenance therapy further enhanced outcomes, with median OS not yet reached in the IMNN-001 treatment arm as patients surpass 5 years since randomization in the trial compared to median OS of 37 months on standard of care